Coronado gets $25.8 million boost to pursue parasite-based autoimmune disease therapy
This article was originally published in Scrip
Executive Summary
Coronado Biosciences is out to help prove that mom is not always right when it comes to cleanliness, and investors, led by National Securities, were willing to give the New York-based biotech $25.8 million to back that up.